Layer-Thickness-Dependent Strengthening–Toughening Mechanisms in Crystalline/Amorphous Nanolaminates by Xiaoling Zhou (4644826)

“…The mechanical performance of these materials is strongly governed by the crystalline–amorphous interfaces (CAIs), yet the underlying strengthening and toughening mechanisms remain poorly understood. Here, we employ large-scale molecular dynamics simulations to investigate the compressive deformation of C/A nanopillars composed of alternating equal-thickness crystalline Cu and amorphous Cu₅₀Zr₅₀ layers. …”

Layer-Thickness-Dependent Strengthening–Toughening Mechanisms in Crystalline/Amorphous Nanolaminates by Xiaoling Zhou (4644826)

“…The mechanical performance of these materials is strongly governed by the crystalline–amorphous interfaces (CAIs), yet the underlying strengthening and toughening mechanisms remain poorly understood. Here, we employ large-scale molecular dynamics simulations to investigate the compressive deformation of C/A nanopillars composed of alternating equal-thickness crystalline Cu and amorphous Cu₅₀Zr₅₀ layers. …”

Fitted kinetics parameters for adsorptions of CR in aqueous solution onto magnetic Co_0.5Mn_0.5Fe₂O₄ nanoparticles at room temperature. by Xiajun Zhang (3161865)

Subjects:

Fig 9 - by Dennis Ochola (11626912)

Fig 7 - by Dennis Ochola (11626912)

Fig 4 - by Dennis Ochola (11626912)

Fluid loss and hydration in CON (n = 22) and HOT (n = 17) surgeries; Decrease in body mass in kg (A), decrease in body mass in % of total body mass (B), rate of decrease in body ma... by Zehra Palejwala (7507409)

Decrease of mitochondrial membrane potential by silvestrol. by Takayuki Kogure (235048)

Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. by Yang Zhang (30734)

Data_Sheet_2_Hepcidin Decreases Rotenone-Induced α-Synuclein Accumulation via Autophagy in SH-SY5Y Cells.ZIP by Meiqi Li (4169182)

“…We demonstrated that SH-SY5Y cell viability was impaired after rotenone treatment in a dose-dependent manner. α-syn expression and iron content increased under a low concentration rotenone (25 nM for 3 days) treatment in SH-SY5Y cells. …”

Data_Sheet_1_Hepcidin Decreases Rotenone-Induced α-Synuclein Accumulation via Autophagy in SH-SY5Y Cells.PDF by Meiqi Li (4169182)

“…We demonstrated that SH-SY5Y cell viability was impaired after rotenone treatment in a dose-dependent manner. α-syn expression and iron content increased under a low concentration rotenone (25 nM for 3 days) treatment in SH-SY5Y cells. …”

Representative immunofluorescence images for S100A6 in brainstem structures in control and stressed mice. by Katarzyna Bartkowska (453261)

Representative immunofluorescence images for S100A6 in some brain structures related to stress responses. by Katarzyna Bartkowska (453261)

CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. by Wanassa Beroual (5314028)

Confocal images of brain sections immunostained with S100A6 and vimentin antibodies. by Katarzyna Bartkowska (453261)

Parasite Load Decrease during Application of a Safe and Easily Applied Antileishmanial Aminoglycoside Cream by Afif Ben Salah (202439)

Bootstrapped LIWC positive word ratio (LWPR) around the hit date for each hurricane and location. by Krishna Bathina (12883820)

GASP mutants initially reach a high population density and subsequently decrease population viability. by Felix J. H. Hol (475373)

Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury by Qiang Li (8118)

“…This study undertakes the modification of a 4-(3-(piperidin-4-yl)-1<i>H</i>-pyrazol-5-yl)pyridine structure, leading to the discovery of 4-(3-(piperidin-4-yl)-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (D25) as a potent and selective MNK inhibitor. …”

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial by Michel Mandro (2637532)

“…<div><p>Introduction</p><p>Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a randomized clinical trial to assess whether ivermectin treatment decreases seizure frequency.…”